Savara (NASDAQ:SVRA – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.
Risk & Volatility
Savara has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.
Earnings and Valuation
This table compares Savara and VYNE Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Savara | N/A | N/A | -$95.88 million | ($0.50) | -8.72 |
| VYNE Therapeutics | $500,000.00 | 19.02 | -$39.83 million | ($0.90) | -0.41 |
VYNE Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Savara and VYNE Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Savara | N/A | -69.05% | -54.84% |
| VYNE Therapeutics | -8,097.69% | -77.57% | -63.09% |
Analyst Ratings
This is a breakdown of recent ratings for Savara and VYNE Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Savara | 1 | 1 | 6 | 1 | 2.78 |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
Savara currently has a consensus price target of $7.83, suggesting a potential upside of 79.66%. VYNE Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 1,574.26%. Given VYNE Therapeutics’ higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than Savara.
Institutional and Insider Ownership
87.9% of Savara shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Savara beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
